1. Home
  2. ESRT vs DSGN Comparison

ESRT vs DSGN Comparison

Compare ESRT & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Empire State Realty Trust Inc.

ESRT

Empire State Realty Trust Inc.

HOLD

Current Price

$5.22

Market Cap

907.0M

Sector

Real Estate

ML Signal

HOLD

Logo Design Therapeutics Inc.

DSGN

Design Therapeutics Inc.

HOLD

Current Price

$12.33

Market Cap

819.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ESRT
DSGN
Founded
2011
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
907.0M
819.6M
IPO Year
2012
2021

Fundamental Metrics

Financial Performance
Metric
ESRT
DSGN
Price
$5.22
$12.33
Analyst Decision
Hold
Strong Buy
Analyst Count
3
4
Target Price
$6.35
$15.25
AVG Volume (30 Days)
2.5M
798.4K
Earning Date
04-29-2026
04-28-2026
Dividend Yield
2.49%
N/A
EPS Growth
N/A
N/A
EPS
0.01
N/A
Revenue
$768,270,000.00
N/A
Revenue This Year
$4.26
N/A
Revenue Next Year
$1.52
N/A
P/E Ratio
$521.50
N/A
Revenue Growth
0.05
N/A
52 Week Low
$4.87
$3.33
52 Week High
$8.39
$17.25

Technical Indicators

Market Signals
Indicator
ESRT
DSGN
Relative Strength Index (RSI) 42.46 58.93
Support Level $4.87 $9.78
Resistance Level $5.83 $13.54
Average True Range (ATR) 0.21 0.63
MACD -0.04 0.25
Stochastic Oscillator 15.28 91.46

Price Performance

Historical Comparison
ESRT
DSGN

About ESRT Empire State Realty Trust Inc.

Empire State Realty Trust Inc is a real estate investment trust (REIT) that owns and operates office, retail, and multifamily properties located in New York City, prominently in Manhattan. Its portfolio includes office and retail space as well as residential units. The company's objective is to maximize cash flow and total returns to its shareholders and to increase the value of the properties. Its reportable segments consist of a real estate segment and an Observatory segment. The majority of revenue is derived from the Real Estate segment, which includes all activities related to the ownership, management, operation, acquisition, redevelopment, repositioning and disposition of its traditional real estate assets.

About DSGN Design Therapeutics Inc.

Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.

Share on Social Networks: